These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34583363)

  • 61. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis.
    Su Y; Wu J; Gu Y
    Photodiagnosis Photodyn Ther; 2018 Jun; 22():263-273. PubMed ID: 29753123
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results.
    Ertan E; Doğan M; Polat O; Efe N; Akdoğan M; İnan S; Duman R; Duman R
    Arq Bras Oftalmol; 2021; 84(3):225-229. PubMed ID: 33567025
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Li F; Sun M; Guo J; Ma A; Zhao B
    Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration.
    Wang Z; Li M; Yao Y; Hu J; Tang J; Tang R; Piao Z; Qu J
    J Ophthalmol; 2020; 2020():9340356. PubMed ID: 33005448
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
    Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
    Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Effect of intravitreal injections of ranibizumab and aflibercept on the retinal nerve fiber layer in patients with concomitant neovascular age-related macular degeneration and glaucoma].
    Rud'ko AS; Budzinskaya MV; Andreeva IV; Karpilova MA; Smirnova TV
    Vestn Oftalmol; 2019; 135(5. Vyp. 2):177-183. PubMed ID: 31691657
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.
    Ye L; Jiaqi Z; Jianchao W; Zhaohui F; Liang Y; Xiaohui Z
    Ther Adv Chronic Dis; 2020; 11():2040622320953349. PubMed ID: 32953000
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration.
    Mantel I; Gillies MC; Souied EH
    Surv Ophthalmol; 2018; 63(5):638-645. PubMed ID: 29476754
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
    Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
    Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis.
    Yin X; He T; Yang S; Cui H; Jiang W
    J Immunol Res; 2022; 2022():6004047. PubMed ID: 35465351
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW
    Retina; 2016 Oct; 36(10):1851-9. PubMed ID: 27074658
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
    Chan CK; Jain A; Sadda S; Varshney N
    Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.